<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070616</url>
  </required_header>
  <id_info>
    <org_study_id>20010182</org_study_id>
    <nct_id>NCT00070616</nct_id>
    <nct_alias>NCT00963170</nct_alias>
  </id_info>
  <brief_title>Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support</brief_title>
  <official_title>An Open-label Study of the Pharmacokinetics (PK) of Recombinant Human Keratinocyte Growth Factor (Palifermin; rHuKGF) in Subjects With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy Followed by Peripheral Blood Progenitor Cell (PBPC) Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <brief_summary>
    <textblock>
      Open label palifermin will be administered to subjects who are at a risk of developing
      mucositis after radiotherapy and chemotherapy followed by blood stem cell support. The amount
      of palifermin in the blood following administration will be evaluated. The safety of
      palifermin administration and its effect on reducing mucositis will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucositis is a common side effect to chemotherapy and radiotherapy involving the formation of
      erythema and ulcerative lesions in the mouth. Mucositis can be serious, resulting in pain
      requiring interventions such as analgesic medications and the use of parenteral feedings.
      Currently, no standard therapy is available to prevent or treat mucositis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the PK profile of 3 daily intravenous (IV) doses of rHuKGF before total body irradiation (TBI) / high-dose chemotherapy conditioning treatment and after PBPC transplantation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of rHuKGF in subjects with hematologic malignancies undergoing TBI and high-dose chemotherapy followed by PBPC transplantation.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess oral mucositis in subjects receiving rHuKGF.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Palifermin 6 x 60 μg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palifermin 2 x 180 μg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin 6 x 60 μg/kg/day</intervention_name>
    <arm_group_label>Palifermin 6 x 60 μg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin 2 x 180 μg/kg/day</intervention_name>
    <arm_group_label>Palifermin 2 x 180 μg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <arm_group_label>Palifermin 6 x 60 μg/kg/day</arm_group_label>
    <arm_group_label>Palifermin 2 x 180 μg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <arm_group_label>Palifermin 6 x 60 μg/kg/day</arm_group_label>
    <arm_group_label>Palifermin 2 x 180 μg/kg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patients diagnosed with Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia and
             Myeloma. - Eligible for treatment with radiation therapy and chemotherapy followed by
             blood stem cell support.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.kepivance.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies. Pharmacotherapy. 2007 Oct;27(10):1353-60.</citation>
    <PMID>17896890</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2003</study_first_submitted>
  <study_first_submitted_qc>October 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2003</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mucositis</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiation therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

